- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Article
FDA clears new drug application for topical psoriasis treatment
The Food and Drug Administration accepted a new drug application for IDP-118 lotion (halobetasol propionate and tazarotene, Ortho Dermatologics), for the topical treatment of plaque psoriasis.
The Food and Drug Administration accepted a new drug application for IDP-118 lotion (halobetasol propionate and tazarotene, Ortho Dermatologics), for the topical treatment of plaque psoriasis.
The lotion, if approved, would be the first of its kind to combine tazarotene and halobetasol propionate in a single formulation for psoriasis in adult patients, according to the company, which is a division of Valeant.
In initial trials, the most common adverse events were application site pain (2.6 percent) and contact dermatitis (7.4 percent).
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
